Diseases are abnormal conditions that have a specific set of signs and symptoms. Diseases can have an external cause, such as an infection, or an internal cause, such as autoimmune diseases.


Latest Research and Reviews

  • Research | | open

    Multiple myeloma is characterized by high rates of drug resistance and relapse. Here the authors utilize a functional assay to assess the ex vivo drug sensitivity of single multiple myeloma cells based on measuring the mass accumulation rate of individual cells.

    • Arif E. Cetin
    • , Mark M. Stevens
    • , Nicholas L. Calistri
    • , Mariateresa Fulciniti
    • , Selim Olcum
    • , Robert J. Kimmerling
    • , Nikhil C. Munshi
    •  & Scott R. Manalis
  • Reviews |

    Lysosomal storage disorders (LSDs) are rare, inherited metabolic disorders that result from defects in lysosomal function, for which treatment options are limited. Here, Platt provides an overview of LSDs, approved and potential therapeutic approaches and agents currently in development. The challenges associated with LSD diagnosis, drug development and treatment are discussed.

    • Frances M. Platt
  • Reviews |

    Sphingolipids, specifically ceramide and sphingosine-1-phosphate, have opposing roles in regulating cancer cell death and survival, respectively. This Review discusses the mechanistic and clinical studies of sphingolipid signalling and metabolism in cancer, highlighting current and emerging therapeutic strategies to target these bioactive lipids.

    • Besim Ogretmen
  • Reviews |

    The causes of migraine remain unknown despite the high prevalence and societal burden of this disorder. Here, the authors highlight how advances in imaging and genetic studies of migraine provide insights into the underlying mechanisms of this disorder; furthermore, they discuss the potential for genetic and imaging biomarkers to improve our ability to prevent and treat migraine attacks.

    • Dale R. Nyholt
    • , David Borsook
    •  & Lyn R. Griffiths
  • Reviews |

    Inadequate remyelination is central to degeneration and disability in patients with multiple sclerosis (MS); however, all currently approved therapies for MS are primarily immunomodulatory. Here, Martin Stangel and colleagues review our current knowledge of remyelination in MS, discuss results from clinical trials of remyelination-enhancing therapies, and evaluate the opportunities for future regenerative treatments.

    • Martin Stangel
    • , Tanja Kuhlmann
    • , Paul M. Matthews
    •  & Trevor J. Kilpatrick

News and Comment